ZeClinics

Playing it safe with traditional models, unsure if alternatives will pass regulatory scrutiny? In today’s drug discovery landscape, not adopting alternative models is no longer optional; the real question is which one to choose. 🔑 Fact Check: Both #EMA and #FDA are increasingly endorsing alternative models, recognizing the significant utility of #zebrafish, particularly for toxicity and efficacy screenings. Regulators validate the use of zebrafish with these key factors in mind: ✅ Integrated Approaches: The trend is shifting towards integrated strategies where zebrafish play a key intermediary role in screening processes. ✅ Complement, Don’t Replace: Use zebrafish models to generate actionable insights early, enhancing decision-making in the selection of compounds and therapeutic targets. ✅ Aligned with the 3Rs: Zebrafish support the 3Rs principle by minimizing animal use in preclinical testing, providing rapid, scalable results that inform more focused and cost-effective mammalian studies. Don’t overlook this powerful tool! Curious to learn how zebrafish can enhance your preclinical testing? Join our webinar! 👉 https://lnkd.in/grrhYFTM

Exciting news from our sister company, ZeNEUROID! 🚀 ZeNEUROID is expanding its team and looking for talented Bioengineering Neuroscientists to push the boundaries of neuropsychiatric research. If you're passionate about iPSC-derived 3D/4D models and ready to make an impact in cutting-edge neuroscience, this could be your next big opportunity! 🧠🔬 Check out the details and apply below! 👇 #Neuroscience #Hiring #ZeNeuroid #ZeClinics

What do Clemizole, Luxturna, and MEK inhibitors have in common? They were all advanced through zebrafish screenings! These groundbreaking compounds made it to clinical trials—and even the market—thanks to zebrafish models. Think Zebrafish Aren’t Relevant to Human Studies? Think Again! Contrary to popular belief, zebrafish are highly translatable to human. 🔑 Fact Check: Zebrafish share 84% of genes associated with human diseases, and their physiology enables results that are highly applicable to human studies. Zebrafish models have successfully predicted drug efficacy in human clinical trials for >10 compounds, especially in areas where rodent models fall short, including: 🧬 Oncology: Leflunomide (melanoma) & Perphenazine (T cell acute lymphoblastic leukaemia) 🧠 Epilepsy: Clemizole and derivatives 🫀 Congenital Heart Disease: MAPK pathway inhibitors (e.g. vemurafenib or trametinib) 👁️ Retinal Regeneration: Luxturna Gene therapy Curious about real-world zebrafish applications? Join our webinar to explore more! https://lnkd.in/grrhYFTM #DrugDiscovery #Biotech #PharmaInnovation #PreclinicalDevelopment #EarlyStageScreening

🐟 Zebrafish: The next leap in drug discovery. Unlock faster, cost-effective insights with whole-organism data. Discover how zebrafish streamline early-stage screening. 👉 Read more in our latest BLOG: https://bit.ly/3NJraJI #DrugDiscovery #ZebrafishModel #BiotechInnovation #PreclinicalResearch #PharmaScience #EarlyStageScreening #LifeSciences #PrecisionMedicine #PharmaResearch #ScientificBreakthrough

ZeClinics is participating in the OECD Workshop on "Critical Innovations in Pesticides Safety Testing and Chemical Risk Assessment for Developmental Neurotoxicity (DNT)" from today to October 30th, at the OECD headquarters in Paris. Valentina Schiavone and Claudia Miguel are thrilled to contribute to discussions shaping the future of chemical safety and developmental neurotoxicity testing. Stay tuned for updates and key insights from the workshop! 🧠🔬 #OECD #ChemicalSafety #Neurotoxicity #ZeClinics #PesticidesSafety #DNT #Innovation

Is Early Gene Therapy Screening Slowing Down Your Research? Speed Up the Early Selection of Your Best Minigene Candidates with Ease. #GeneTherapy is transformative—but identifying the right genetic fragments is a major bottleneck. Early screening of multiple #minigenes can be costly, time-consuming, and full of uncertainties when relying solely on mammalian models. You need a way to evaluate dozens of candidates quickly, accurately, and cost-effectively. Our zebrafish platform provides a streamlined way to conduct early-stage gene therapy screenings. Using advanced tools like CRISPR/Cas9 and Tol2, you can quickly generate disease-specific models and: ✔Rapidly create genetic disease models to replicate patient-specific conditions. ✔Evaluate the efficacy of multiple minigenes, finding the most promising candidates faster. ✔Minimize mammalian testing, focusing only on the best genetic fragments for more advanced stages. Discover how to simplify the process and find the best candidates faster in our upcoming webinar. FREE REGISTRATION here! https://lnkd.in/grrhYFTM #DrugDiscovery #Biotech #PharmaInnovation #PreclinicalDevelopment #EarlyStageScreening

Struggling to Quickly Generate Patient-Specific Mutation Models? Accelerate drug screening tailored to patients' unique genetic profiles effortlessly. With tools like CRISPR/Cas9 and Tol2, zebrafish offer rapid and flexible genetic editing, making it possible to: ✅Develop models for specific patient mutations in record time. ✅Discover the clinical relevance of specific mutations with efficiency. ✅Identify the optimal treatment for each unique genetic profile with high-throughput drug screenings. Ready to bring precision medicine to patients? 🖥 Join our webinar to learn how custom zebrafish models can make it possible Save your spot here: https://lnkd.in/grrhYFTM #DrugDiscovery #Biotech #PharmaInnovation #PreclinicalDevelopment #EarlyStageScreening

Finding it Challenging to Model Complex Diseases? Many diseases are notoriously difficult to model with conventional animal systems, limiting research breakthroughs. Zebrafish are changing that. They provide powerful modeling opportunities for diseases poorly represented in traditional models. Zebrafish models have been crucial in advancing the understanding and treatment of complex diseases: 🔬 Neurodegenerative disorders—Advancing research in Parkinson’s and Alzheimer’s disease, providing crucial insights into the dopaminergic system. 🫀 Cardiovascular disorders—Revealing insights into heart failure and regeneration.  👁️ Ophthalmology—Tackling retinal diseases and age-related macular degeneration (AMD).  🧬 Oncology—Tracking tumor growth, metastasis, and real-time cancer progression. Zebrafish provide genetically comparable systems, making them instrumental in accelerating drug discovery, especially in neurodegenerative diseases, where they can accelerate the process by up to 50%. Ready to overcome the challenges of modeling complex diseases? Discover how zebrafish can provide the disease models you need to accelerate breakthroughs in your research. Join our free webinar to learn more! 👉 https://lnkd.in/grrhYFTM #DrugDiscovery #Biotech #PharmaInnovation #PreclinicalDevelopment #EarlyStageScreening

Introducing a Game-Changing Approach for Early-Stage Drug Screening ➡️An intermediary model designed to enhance early-stage screening in drug discovery. 🔑 Watch the video to uncover the key benefits of our innovative approach! ✅ Actionable Insights ✅ Stronger statistical power ✅ Achieve results faster ✅ Cost-Effective ✅ Ethical Want to know how it works? Register for our webinar today! https://lnkd.in/grrhYFTM 🔄 Stay tuned for more benefits in our next post!

FREE WEBINAR Session 2: From Vision to Strategy! Refine Your Early-Stage Drug Screening Learn a transformative approach that will help you slash costs and accelerate preclinical drug screenings, while increasing success rates in your predictions. ☑Efficiently screen compounds in vivo in weeks, not months ☑Gain actionable insights earlier to optimize hit selection before expensive mammalian testing ☑Improve the relevance of preclinical data to clinical outcomes ☑Model previously hard-to-study diseases with ease Register now to session 2 👇